CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

2.88
0  0%
Previous Close 2.88
Open
Price To Book 2.94
Market Cap 9,573,276
Shares 3,324,054
Volume 1,742
Short Ratio 0.15
Av. Daily Volume 285,821

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Glaucoma
Phase 2 data did not meet primary endpoint - March 27, 2019.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 continues to enrol as of May 29, 2019.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 21, 2018.
Piclidenoson (CF101)
Psoriasis
Phase 2 data due 2H 2019.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
  2. Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
  3. Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update
  4. Secondary Offerings Put A Pause On May's Momentum
  5. The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
  6. Can-Fite BioPharma Announces $6 Million Registered Direct Offering
  7. Can-Fite Abstract Selected For Liver Conference
  8. Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
  9. Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
  10. Can-Fite Announces ADS Ratio Change
  11. Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
  12. Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
  13. Can-Fite Files Annual Report for the Year Ended December 31, 2018
  14. Can-Fite Reports 2018 Financial Results & Provides Clinical Update
  15. Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
  16. Four Marijuana Stocks on the Rise on Wednesday
  17. Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo
  18. Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
  19. Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)